Ecolectro | $10,500,000 | (Nov 15, 2024)
Workflow | $3,000,000 | (Nov 15, 2024)
runQL | $1,600,000 | (Nov 15, 2024)
Healx
United Kingdom
- Cambridge, Cambridgeshire
- 02/08/2024
- Series C
- $47,000,000
Healx is a mission-driven technology company pioneering the next generation of drug discovery in order to bring novel, effective treatments to rare disease patients around the world. There are 7,000 known rare diseases that affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining frontier AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale and improve the chance of success of rare disease treatment development in order to meet this huge unmet need and have unprecedented patient impact.
- Industry Biotechnology Research
- Website https://healx.ai/
- LinkedIn https://www.linkedin.com/company/healx/
Related People
Tim GuilliamsCo Founder
United Kingdom -
Greater Cambridge Area
Tim is a tech bio founder from the Cambridge Cluster (UK), passionate about using AI to accelerate treatments for rare diseases.
He is the Co-founder and Chief Executive of Healx Ltd, an AI-powered, patient-inspired biotech company, accelerating the discovery and development of rare disease treatments at scale. Healx raised over a $100M to date and won numerous awards.
As CEO of Healx, Tim won the 'WellFounded Founder/CEO Leadership Award' recognising innovative leaders making significant contributions to HeathTech and PatientImpact, while prioritising a healthy workspace. He has been listed in The Sunday Times Maserati 100 list of entrepreneurs, The Telegraph’s Tech 100, In Vivo’s 30 Rising Leaders in the Life Sciences etc.
Tim is also the Co-founder and Trustee of a charity named CamRARE / Cambridge Rare Disease Network. Prior to Healx and CamRARE, he obtained his PhD at the University of Cambridge in the field of Biophysics and Neuroscience.
Before moving to Cambridge UK, Tim obtained an MEng in Bio- and Chemical-Engineering from the University of Brussels.
ELICIT PLANT | $48,000,000 | (Nov 15, 2024)
Sunthetics | $4,000,000 | (Nov 15, 2024)
Vaulted Deep | $32,300,000 | (Nov 15, 2024)
Serenity | $5,500,000 | (Nov 15, 2024)
Airbound | $1,700,000 | (Nov 15, 2024)
Influur | $10,000,000 | (Nov 15, 2024)
Naturbeads | $9,890,632 | (Nov 15, 2024)
TestSprite | $1,500,000 | (Nov 15, 2024)
Impilo | $11,500,000 | (Nov 15, 2024)